Advanced Search
CHAI Xiaofei, QIAO Honghan, ZHANG Lei, LI Xin, LI Ling, WANG Xinhua, FU Xiaorui, ZHANG Xudong, SUN Zhenchang, NAN Feifei, ZHANG Mingzhi. Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 288-292. DOI: 10.3971/j.issn.1000-8578.2023.22.1235
Citation: CHAI Xiaofei, QIAO Honghan, ZHANG Lei, LI Xin, LI Ling, WANG Xinhua, FU Xiaorui, ZHANG Xudong, SUN Zhenchang, NAN Feifei, ZHANG Mingzhi. Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 288-292. DOI: 10.3971/j.issn.1000-8578.2023.22.1235

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy

Funding: 

National Natural Science Foundation of China 81970184

National Natural Science Foundation of China 82170183

Department of Science and Technology of Henan Province 182102310114

More Information
  • Corresponding author:

    ZHANG Mingzhi,E-mail: mingzhi_zhang1@163.com

  • Received Date: October 18, 2022
  • Revised Date: December 26, 2022
  • Available Online: January 12, 2024
  • Objective 

    To retrospectively evaluate the clinical efficacy and safety of brentuximab vedotin(BV) combined with chemotherapy in the treatment of malignant lymphoma.

    Methods 

    We collected the data of 32 lymphoma patients with CD30-positive status, including 14 cases of Hodgkin's lymphomas, 2 cases of diffuse large B-cell lymphomas, and 16 cases of mature T/NK cell lymphomas. Chemotherapy combined with BV was administered to all patients for a minimum of two cycles. The efficacy of the treatment was evaluated according to Lugano criteria every two cycles.

    Results 

    Complete response rate and overall response rate after four cycles of treatment were 22% and 50%, respectively. Sixteen cases (50.0%) had grades 1 and 2 toxicity, and 16 cases (50.0%) had grade 3 toxicity or higher. The most common adverse events were neutropenia (50.0%), pneumonia (46.9%), and anemia (43.8%). The most common grade 3 or higher adverse events were pneumonia (18.8%) and febrile neutropenia (12.5%). Four patients discontinued brentuximab vedotin because of severe adverse events.

    Conclusion 

    BV is effective in treating relapsed and refractory CD30- positive Hodgkin's lymphoma and peripheral T-cell lymphoma, and its overall safety is acceptable.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Scott LJ. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma[J]. Drugs, 2017, 77(4): 435-445. doi: 10.1007/s40265-017-0705-5
    [2]
    缪祎, 徐卫. 维布妥昔单抗治疗CD30阳性外周T细胞淋巴瘤的研究进展[J]. 中国肿瘤临床, 2022, 49(12): 627-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202212006.htm

    Miao Y, Xu W. Research advances of brentuximab vedotin in the treatment of CD30+ peripheral T-cell lymphoma[J]. Zhongguo Zhong Liu Lin Chuang, 2022, 49(12): 627-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202212006.htm
    [3]
    Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3067. doi: 10.1200/JCO.2013.54.8800
    [4]
    Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study[J]. Lancet Haematol, 2018, 5(10): e450-e461. doi: 10.1016/S2352-3026(18)30153-4
    [5]
    Stein H, Mason D, Gerdes J, et al. The expression of the Hodgkin' s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells[J]. Blood, 1985, 66(4): 848-858. doi: 10.1182/blood.V66.4.848.848
    [6]
    Sperling S, Fiedler P, Lechner M, et al. Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells[J]. Blood, 2019, 133(24): 2597-2609. doi: 10.1182/blood.2018880138
    [7]
    Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic largecell lymphoma: Results of a phaseⅡ study[J]. J Clin Oncol, 2012, 30(18): 2190-2196. doi: 10.1200/JCO.2011.38.0402
    [8]
    Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas[J]. F1000Res, 2020, 9 : F1000 Faculty Rev-1091.
    [9]
    Tournilhac O, Hacini M, Bouabdallah K, et al. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, PhaseⅡ Study. "the TOTAL Trial"[J]. Blood, 2020, 136(Suppl 1): 15-16.
    [10]
    Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168): 229-240. doi: 10.1016/S0140-6736(18)32984-2
    [11]
    Kanate AS, Kumar A, Dreger P, et al. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT[J]. JAMA Oncol, 2019, 5(5): 715-722. doi: 10.1001/jamaoncol.2018.6278
    [12]
    Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial[J]. Lancet Oncol, 2018, 19(9): 1229-1238. doi: 10.1016/S1470-2045(18)30426-1
    [13]
    Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1[J]. Blood, 2021, 137(26): 3595-3603. doi: 10.1182/blood.2020009806
  • Related Articles

    [1]XU Tian, YANG Lu, YUAN Fangqin, HE Xia, YIN Li. Relation Between EB Virus Infection and Curative Effect, Prognosis of Patients with Early-stage Extranodal Nasal-type NK/T-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 999-1005. DOI: 10.3971/j.issn.1000-8578.2021.21.0216
    [2]XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878
    [3]DONG Fei, PANG Meng, ZHENG Dong, ZHEN Jingfei, JING Hongmei. Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 515-518. DOI: 10.3971/j.issn.1000-8578.2019.18.1561
    [4]GAO Fan, WANG Jing, KE Xiaoyan. Diagnosis and Prognosis of Non-Hodgkin's Lymphoma with Bone Marrow Involvement[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 598-603. DOI: 10.3971/j.issn.1000-8578.2018.18.0061
    [5]YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang. Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751
    [6]SONG Teng, LIANG Shaoping, LI Jingmin, CHEN Haizhu, LI Shuping, WANG Huaqing. Clinical Characteristics and Prognosis of 123 Patients with Diffuse Large B-cell Lymphoma of Waldeyer’s Ring[J]. Cancer Research on Prevention and Treatment, 2016, 43(5): 382-386. DOI: 10.3971/j.issn.1000-8578.2016.05.013
    [7]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [8]YU Wei-wei, WANG Hua-qing, QIAN Zheng-zi, CUI Xiu-zhen, HAO Xi-shan. Clinical Characteristics and Prognosis Analysis of Primary Mediastinal Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 647-650. DOI: 10.3971/j.issn.1000-8578.2011.06.010
    [9]HE Bin-bin, YANG Bin. Analysis of Clinicopathological Characters and Outcomes of 45 Patients with Anaplastic Large Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 59-62. DOI: 10.3971/j.issn.1000-8578.2011.01.017
    [10]LUO Rui, SUN Jun-mo, LONG Qing-yun, TIAN Zhi-xiong. Non-Hodgkin s Lymphoma of Nasal Cavity:CT Diagnosis and Clinical Prognosis[J]. Cancer Research on Prevention and Treatment, 2004, 31(10): 623-626. DOI: 10.3971/j.issn.1000-8578.2563

Catalog

    Figures(1)  /  Tables(4)

    Article views (2508) PDF downloads (685) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return